| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2927 |
| Trial ID | NCT05231369 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | ChulaCov19 BNA159 mRNA Vaccine |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Study to Evaluate Safety, Immunogenicity of the ChulaCov19 BNA159 mRNA Vaccine in Healthy Adults |
| Year | 2022 |
| Country | Australia|China|Korea,Republic of|New Zealand|Thailand |
| Company sponsor | Chulalongkorn University |
| Other ID(s) | ChulaVac 003 |
| Vector information | |||
|
|||
| Cohort1: ChulaCov19 BNA159 mRNA vaccine_dose level 1 | |||||||||
|
|||||||||
| Cohort2: ChulaCov19 BNA159 mRNA vaccine_dose level 2 | |||||||||
|
|||||||||